BridgeBio Pharma, Inc. (LS:A2PLX7) Financings
Financings
| Raise | Date |
|---|---|
| Preferred equity Closed: US$1B raised Buyers: Sixth Street (led the financing); HealthCare Royalty Use of proceeds: Fund three potential upcoming launches while continuing to invest in indication expansion across the pipeline | Aug 10, 2026 |
| Series A Cumulative Convertible Participating Preferred Stock Closed: convertible Buyers: Sixth Street (funded $800M as the lead investor); HealthCare Royalty (funded $133.9M) Use of proceeds: Strengthen the balance sheet and allocate capital across its highest return opportunities, including product launches | Jul 1, 2026 |
| 0.75% convertible senior notes due 2033 Update: US$550M Use of proceeds: Repurchase, settle conversions of or repay part of the 2.50% convertible notes due 2027, and general corporate purposes | Jan 15, 2026 |
| 1.75% convertible senior notes due 2031 Update: US$500M Use of proceeds: Repay and terminate the Blue Owl Financing Agreement, repurchase about $48.3 million of common stock, and general corporate purposes | Feb 25, 2025 |